Virbac Sa Stock Net Income
| VRBCF Stock | USD 346.00 0.00 0.00% |
In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Virbac SA, as well as the relationship between them.
Virbac SA's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Virbac SA's valuation are provided below:Virbac SA does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Virbac |
Virbac SA 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Virbac SA's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Virbac SA.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Virbac SA on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Virbac SA or generate 0.0% return on investment in Virbac SA over 90 days. Virbac SA is related to or competes with Haw Par, Haw ParLimited, Santen Pharmaceutical, GN Store, Hypera SA, Bavarian Nordic, and GN Store. Virbac SA manufactures and sells a range of products and services for companion and food-producing animals in France, Eu... More
Virbac SA Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Virbac SA's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Virbac SA upside and downside potential and time the market with a certain degree of confidence.
Virbac SA Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Virbac SA's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Virbac SA's standard deviation. In reality, there are many statistical measures that can use Virbac SA historical prices to predict the future Virbac SA's volatility.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Virbac SA's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Virbac SA Backtested Returns
We have found three technical indicators for Virbac SA, which you can use to evaluate the volatility of the company. The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Virbac SA are completely uncorrelated.
Auto-correlation | 0.00 |
No correlation between past and present
Virbac SA has no correlation between past and present. Overlapping area represents the amount of predictability between Virbac SA time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Virbac SA price movement. The serial correlation of 0.0 indicates that just 0.0% of current Virbac SA price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Virbac SA reported net income of 113.16 M. This is 66.84% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The net income for all United States stocks is 80.18% higher than that of the company.
Virbac Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Virbac SA's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Virbac SA could also be used in its relative valuation, which is a method of valuing Virbac SA by comparing valuation metrics of similar companies.Virbac SA is currently under evaluation in net income category among its peers.
Virbac Fundamentals
| Return On Equity | 0.15 | |||
| Return On Asset | 0.091 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 2.1 B | |||
| Shares Outstanding | 8.44 M | |||
| Shares Owned By Insiders | 50.38 % | |||
| Shares Owned By Institutions | 25.63 % | |||
| Price To Earning | 18.33 X | |||
| Price To Book | 4.58 X | |||
| Price To Sales | 2.93 X | |||
| Revenue | 1.06 B | |||
| Gross Profit | 712.85 M | |||
| EBITDA | 208.43 M | |||
| Net Income | 113.16 M | |||
| Cash And Equivalents | 174.57 M | |||
| Cash Per Share | 20.67 X | |||
| Total Debt | 13.15 M | |||
| Debt To Equity | 0.14 % | |||
| Current Ratio | 1.68 X | |||
| Book Value Per Share | 96.99 X | |||
| Cash Flow From Operations | 129.9 M | |||
| Earnings Per Share | 13.65 X | |||
| Number Of Employees | 5.12 K | |||
| Beta | 0.88 | |||
| Market Capitalization | 3.38 B | |||
| Total Asset | 1.2 B | |||
| Annual Yield | 0 % | |||
| Net Asset | 1.2 B | |||
| Last Dividend Paid | 1.25 |
About Virbac SA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Virbac SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Virbac SA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Virbac SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Virbac Pink Sheet
Virbac SA financial ratios help investors to determine whether Virbac Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Virbac with respect to the benefits of owning Virbac SA security.